Opendata, web and dolomites

SELNET SIGNED

Sarcoma as a model to improve diagnosis and clinical care of rare tumors through a European and Latin American multidisciplinary network

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SELNET project word cloud

Explore the words cloud of the SELNET project. It provides you a very rough idea of what is the project "SELNET" about.

healthcare    medical    solid    risk    survival    absence    cpgs    core    worsen    poor    conduct    brazil    drivers    policies    italy    create    rcs    networks    group       latin    relapse    sarcoma    care    replicable    financial    representing    incidence    peru    pathologists    adult    intercontinental    scarcity    cancersrare    prognostic    death    deaths    diagnoses    sarcomas    american    countries    boards    delayed    improvement    spain    models    unavailability    education    collaborative    complete    30    registry    costa    lack    guidelines    pathological    22    france    selnet    network    threatening    adherence    patients    accounting    life    drugs    trials    specialists    creation    patient    expertise    subtypes    groups    celac    therapies    tissues    quality    biobanks    observational    expert    centers    tumor    cancer    mexico    barrier    reference    hindered    malignancies    bone    preclinical    incorrect    validating    community    caribbean    10    strategic    diagnosis    appropriate    model    mtbs    translational    heterogeneous    hence    data    referral    rica    cancers    argentina    prognosis    soft    international    tumors    rare    practitioners    clinical    multidisciplinary   

Project "SELNET" data sheet

The following table provides information about the project.

Coordinator
SERVICIO ANDALUZ DE SALUD 

Organization address
address: AVENIDA DE LA CONSTITUCION 18
city: SEVILLA
postcode: 41071
website: http://www.sas.junta-andalucia.es/principal/default.asp

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 3˙294˙306 €
 EC max contribution 3˙092˙400 € (94%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2018-Single-Stage-RTD
 Funding Scheme RIA
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2022-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SERVICIO ANDALUZ DE SALUD ES (SEVILLA) coordinator 792˙000.00
2    CENTRE DE LUTTE CONTRE LE CANCER LEON BERARD FR (LYON) participant 486˙000.00
3    FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI IT (Milan) participant 450˙000.00
4    ISTITUTO ORTOPEDICO RIZZOLI IT (BOLOGNA) participant 432˙000.00
5    GRUPO ESPANOL DE INVESTIGACION EN SARCOMAS ASOCIACION ES (MADRID) participant 306˙000.00
6    ALEXANDER FLEMING SA AR (BUENOS AIRES) participant 194˙400.00
7    FUNDACION AMOR ESPERANZA Y VIDA CR (HEREDIA) participant 180˙000.00
8    INSTITUTO NACIONAL DE ENFERMEDADES NEOPLASICAS-INEN PE (LIMA) participant 176˙400.00
9    SARCOMA PATIENTS EURONET EV DE (WOLFERSHEIM) participant 75˙600.00
10    FUNDACAO ANTONIO PRUDENTE BR (SAO PAULO) participant 0.00
11    Instituto Nacional de Cancerología MX (MEXICO) participant 0.00

Map

 Project objective

Rare cancersRare cancers are associated with poor survival, accounting for 22% of new cancer diagnoses in Europe, and 30% of cancer deaths. Sarcomas are a heterogeneous group of life-threatening rare solid malignancies affecting soft and bone tissues, representing 10% of rare tumors and around 2% of adult tumors, with an incidence of 5.9/100,000/year in Europe. Appropriate management of sarcoma patients is hindered by the absence of referral policies to reference centers (RCs), incorrect or delayed diagnosis, non-adherence of therapies to clinical practice guidelines (CPGs), and lack of expertise by practitioners, which increases the risk of relapse and death. These problems worsen in the Community of Latin American and Caribbean States (CELAC) due to the scarcity or complete unavailability of RCs, expert pathologists, multidisciplinary tumor boards (MTBs), new cancer drugs, clinical trials, patient registry data, and financial resources. Hence, the SELNET project seeks to create a European and Latin American multidisciplinary network of clinical and translational specialists to improve diagnosis and clinical care in sarcomas, with the aim of validating a collaborative model replicable in other rare tumors and in other countries. Recognized cancer centers and research groups of Spain, Italy, France, Mexico, Brazil, Argentina, Costa Rica, and Peru will contribute to better rare cancer care by fostering RCs, healthcare barrier analysis, CPGs, and medical education as key improvement drivers. The core of the research work focuses on improving diagnosis and prognosis of sarcoma patients through the creation of pathological diagnosis networks, MTBs, the conduct of an international registry-based observational study to assess clinical management quality and prognostic factors, and the implementation of an strategic translational research program to develop intercontinental sarcoma biobanks, preclinical models, and a translational study with drugs in rare sarcoma subtypes.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SELNET" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SELNET" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More  

INADVANCE (2019)

Patient-centred pathways of early palliative care, supportive ecosystems and appraisal standard

Read More